Idt Australia Limited · ASX:IDT
Idt Australia — Australia Biotech Invest 2013
11 slides from Idt Australia's conference presentation, Oct 28, 2013
Slide 1: Australia Biotech Invest 2013
AUSTRALIA BIOTECH INVEST 2013 Investor Highlights: ‘Established in 1975 as a contract drug development company, $10.2m revenues in 2012 *API, finished dose form and clinical capabilities ‘Facilities, experience and regulatory y packages have set the platform for a rapid move into generic oncology dr
Slide 2: New Management Team: Driving Growth and Value
New Management Team: Driving Growth and Value A. Organic business growth and a return to profitability through better sales and marketing, and efficiencies C. Transformational high value assets accelerated by IDT capabilities and skills: pro-drugs and super-generics cy Japanese pharma opportunities
Slide 3: Melbourne Manufacturing Campus
Melbourne Manufacturing Campus 12,000m2 freehold site $70m+ replacement value, $10m unimproved land value 1. Engineering 2. Warehouses/ inward goods Cytotoxic labs Dev. labs Administration Controlled store Antibiotic API/FP HPAP! + sterile 0) (98 Spee ge ee mail Utilities i | |e | il 10. Oraldose fo
Slide 4: Melbourne Site Virtual Tour
Melbourne Site Virtual Tour |
Slide 5: CMAX: Royal Adelaide Hospital
CMAX: Royal Adelaide Hospital * 445 studies completed over 20yrs ¢ Australia’s largest clinical trial unit * More patients safely and successfully dosed than any other facility * Access to healthy volunteers and clinical patients innovation compliance
Slide 6: Years Experience in Dangerous and Difficult to Manufacture Drugs
30 Years Experience in Dangerous and Difficult to Manufacture Drugs Synth. Conj. Estrogens ($35m) Pentosan ($230m) OO Temozolomide ($1b) Thiotepa ($85m) Temsirolimus ($300m) Ertapenem ($380M) innovation containment compliance ict
Slide 7: Abbreviated New Drug Application (ANDA)
Amended New Drug Application (ANDA) ¢ Process for registering a generic drug in the US one O O O O © Po. 3 Stability oC MC package Batches (+ bioequivalence O O data for oral drugs) O O 2,0 Simple Generic Registration Oncology Process Portfolio e | . , innovation c compliance australia) 09
Slide 8: Moving up the Value Chain
Moving up the Value Chain ¢ Case Study, Drug X: ¢ IDT currently the dominant supplier of API into a large market, yet capturing a less than 1% as an API supplier * Registration and supply of 50.00% Finished Dose Form could increase IDT’s share of value chain to approximately 50% ¢« There are a numbe
Slide 9: Corporate Snapshot
Corporate Snapshot ¢as at 230ct13) Financials =" 1 year trading history, « 2012 2013 duh Rev $9.9m $10.6m os EBIT ($3.6) ($4.4) Cash use ($1.4) ($2.2) Debt $1.95m omer _ a . . retin 5 year trading history « Register ¢ 75.56 m shares on issue * 500,000 options (unlisted) ¢ Top 20 holders 61.5% (220ct
Slide 10: Summary
Summary * $70M+ purpose-built drug manufacturing and development facility, ample capacity for growth ® Australia’s largest and only private clinical trials unit ® Reliable base revenues from drug development, drug manufacture, clinical trials ® 30 year history has resulted in the ownership of multip
Slide 11: For personal use only
Managing Director +61 3 9801-8888 info@idtaus.com.au